IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial

Eduard Shantsila, Ronnie Haynes, Melanie Calvert, James Fisher, Paulus Kirchhof, Paramjit S Gill, Gregory Y H Lip, Eduard Shantsila, Ronnie Haynes, Melanie Calvert, James Fisher, Paulus Kirchhof, Paramjit S Gill, Gregory Y H Lip

Abstract

Introduction: Patients with atrial fibrillation frequently suffer from heart failure with preserved ejection fraction. At present there is no proven therapy to improve physical capacity and quality of life in participants with permanent atrial fibrillation with preserved left ventricular contractility.

Objective: The single-centre IMproved exercise tolerance In heart failure With PReserved Ejection fraction by Spironolactone On myocardial fibrosiS In Atrial Fibrillation (IMPRESS-AF) trial aims to establish whether treatment with spironolactone as compared with placebo improves exercise tolerance (cardiopulmonary exercise testing), quality of life and diastolic function in patients with permanent atrial fibrillation.

Methods and analysis: A total of 250 patients have been randomised in this double-blinded trial for 2-year treatment with 25 mg daily dose of spironolactone or matched placebo. Included participants are 50 years old or older, have permanent atrial fibrillation and ejection fraction >55%. Exclusion criteria include contraindications to spironolactone, poorly controlled hypertension and presence of severe comorbidities with life expectancy <2 years. The primary outcome is improvement in exercise tolerance at 2 years and key secondary outcomes include quality of life (assessed using the EuroQol EQ-5D-5L (EQ-5D) and Minnesota Living with Heart Failure (MLWHF) questionnaires), diastolic function and all-cause hospitalisation.

Ethics and dissemination: The study has been approved by the National Research and Ethics Committee West Midlands-Coventry and Warwickshire (REC reference number 14/WM/1211). The results of the trial will be published in an international peer-reviewed journal.

Trial registration numbers: EudraCT2014-003702-33; NCT02673463; Pre-results.

Keywords: atrial fibrillation; exercise tolerance; heart failure with preserved ejection fraction; spironolactone.

Conflict of interest statement

Conflicts of Interest: None declared.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Figures

Figure 1
Figure 1
Trial schema. BNP, brain natriuretic peptide; CPET, cardio-pulmonary exercise testing; eGRF, estimated glomerular filtration rate; FBC, full blood count and haematocrit; GP, general practitioner; QoL, quality of life; RC-CCS, Research clinic of the University of Birmingham Institute for Cardiovascular Sciences, City Hospital, Birmingham, UK.

References

    1. McMurray JJ, Adamopoulos S, Anker SD et al. . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787–847. 10.1093/eurheartj/ehs104
    1. Tsang TS, Barnes ME, Gersh BJ et al. . Risks for atrial fibrillation and congestive heart failure in patients >/=65 years of age with abnormal left ventricular diastolic relaxation. Am J Cardiol 2004;93:54–8. 10.1016/j.amjcard.2003.09.012
    1. Tsang TS, Gersh BJ, Appleton CP et al. . Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002;40:1636–44. 10.1016/S0735-1097(02)02373-2
    1. Santhanakrishnan R, Wang N, Larson MG et al. . Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved vs. reduced ejection fraction. Circulation 2016;133:484–9210.1161/CIRCULATIONAHA.115.018614.
    1. Fonarow GC, Stough WG, Abraham WT et al. . Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007;50:768–77. 10.1016/j.jacc.2007.04.064
    1. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 2010;55:526–37. 10.1016/j.jacc.2009.06.067
    1. Linssen GC, Rienstra M, Jaarsma T et al. . Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 2011;13:1111–20. 10.1093/eurjhf/hfr066
    1. Olsson LG, Swedberg K, Ducharme A et al. . Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006;47:1997–2004. 10.1016/j.jacc.2006.01.060
    1. McKelvie RS, Komajda M, McMurray J et al. . Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail 2010;16:128–34. 10.1016/j.cardfail.2009.09.007
    1. Fung JW, Sanderson JE, Yip GW et al. . Impact of atrial fibrillation in heart failure with normal ejection fraction: a clinical and echocardiographic study. J Card Fail 2007;13:649–55. 10.1016/j.cardfail.2007.04.014
    1. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004;350:1953–9. 10.1056/NEJMoa032566
    1. Redfield MM, Jacobsen SJ, Borlaug BA et al. . Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation 2005;112:2254–62. 10.1161/CIRCULATIONAHA.105.541078
    1. Lam CS, Roger VL, Rodeheffer RJ et al. . Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007;115:1982–90. 10.1161/CIRCULATIONAHA.106.659763
    1. Westermann D, Kasner M, Steendijk P et al. . Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008;117:2051–60. 10.1161/CIRCULATIONAHA.107.716886
    1. Kitzman DW, Higginbotham MB, Cobb FR et al. . Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol 1991;17:1065–72. 10.1016/0735-1097(91)90832-T
    1. Ahmed SH, Clark LL, Pennington WR et al. . Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006;113:2089–96. 10.1161/CIRCULATIONAHA.105.573865
    1. Martos R, Baugh J, Ledwidge M et al. . Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007;115:888–95. 10.1161/CIRCULATIONAHA.106.638569
    1. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689–97. 10.1056/NEJMra000050
    1. Burniston JG, Saini A, Tan LB et al. . Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo. J Mol Cell Cardiol 2005;39:395–9. 10.1016/j.yjmcc.2005.04.001
    1. Brilla CG, Zhou G, Matsubara L et al. . Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809–20. 10.1006/jmcc.1994.1098
    1. Tsai CT, Chiang FT, Tseng CD et al. . Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 2010;55:758–70. 10.1016/j.jacc.2009.09.045
    1. Edelmann F, Schmidt AG, Gelbrich G et al. . Rationale and design of the ‘aldosterone receptor blockade in diastolic heart failure’ trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur J Heart Fail 2010;12:874–82. 10.1093/eurjhf/hfq087
    1. Edelmann F, Wachter R, Schmidt AG et al. . Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013;309:781–91. 10.1001/jama.2013.905
    1. Shah SJ, Heitner JF, Sweitzer NK et al. . Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2013;6:184–92. 10.1161/CIRCHEARTFAILURE.112.972794
    1. Desai AS, Lewis EF, Li R et al. . Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011;162:966–72.e10. 10.1016/j.ahj.2011.09.007
    1. Mahadevan G, Davis RC, Frenneaux MP et al. . Left ventricular ejection fraction: are the revised cut-off points for defining systolic dysfunction sufficiently evidence based? Heart 2008;94:426–8. 10.1136/hrt.2007.123877
    1. Kyte D, Duffy H, Fletcher B et al. . Systematic evaluation of the patient-reported outcome (PRO) content of clinical trial protocols. PLoS ONE 2014;9:e110229 10.1371/journal.pone.0110229
    1. Calvert M, Kyte D, Duffy H et al. . Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers. PLoS ONE 2014;9:e110216 10.1371/journal.pone.0110216
    1. Calvert M, Kyte D, von Hildebrand M et al. . Putting patients at the heart of health-care research. Lancet 2015;385:1073–4. 10.1016/S0140-6736(15)60599-2
    1. Camm AJ, Lip GY, De Caterina R et al. . 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719–47.
    1. Camm AJ, Kirchhof P, Lip GY et al. , European Heart Rhythm A, European Association for Cardio-Thoracic S. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369–429. 10.1093/eurheartj/ehq278
    1. Lang RM, Bierig M, Devereux RB et al. . Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79–108. 10.1016/j.euje.2005.12.014
    1. Rector TS, Carson PE, Anand IS et al. . Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the Minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail 2012;5:217–25. 10.1161/CIRCHEARTFAILURE.111.964221
    1. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 1993;71:1106–7. 10.1016/0002-9149(93)90582-W
    1. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992;124:1017–25. 10.1016/0002-8703(92)90986-6
    1. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53–72. 10.1016/0168-8510(96)00822-6
    1. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337–43. 10.3109/07853890109002087
    1. Zannad F, Alla F, Dousset B et al. . Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700–6. 10.1161/01.CIR.102.22.2700
    1. Sohn DW, Song JM, Zo JH et al. . Mitral annulus velocity in the evaluation of left ventricular diastolic function in atrial fibrillation. J Am Soc Echocardiogr 1999;12:927–31.
    1. Kusunose K, Yamada H, Nishio S et al. . Clinical utility of single-beat E/e’ obtained by simultaneous recording of flow and tissue Doppler velocities in atrial fibrillation with preserved systolic function. JACC Cardiovasc Imaging 2009;2:1147–56. 10.1016/j.jcmg.2009.05.013
    1. Aljaroudi W, Alraies MC, Halley C et al. . Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction. Circulation 2012;125:782–8. 10.1161/CIRCULATIONAHA.111.066423
    1. Nagueh SF, Kopelen HA, Quinones MA. Assessment of left ventricular filling pressures by Doppler in the presence of atrial fibrillation. Circulation 1996;94:2138–45.
    1. Temporelli PL, Scapellato F, Corrà U et al. . Estimation of pulmonary wedge pressure by transmitral Doppler in patients with chronic heart failure and atrial fibrillation. Am J Cardiol 1999;83:724–7.
    1. Chirillo F, Brunazzi MC, Barbiero M et al. . Estimating mean pulmonary wedge pressure in patients with chronic atrial fibrillation from transthoracic Doppler indexes of mitral and pulmonary venous flow velocity. J Am Coll Cardiol 1997;30:19–26.
    1. Nagueh SF, Smiseth OA, Appleton CP et al. . Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277–314. 10.1016/j.echo.2016.01.011
    1. Hussain S, Mohammed M, Haque M et al. . A simple method to ensure plausible multiple imputation for continuous multivariate data. Commun Stat Simulation Comput 2010;39:1779–84. 10.1080/03610918.2010.518267
    1. Cicoira M, Zanolla L, Rossi A et al. . Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002;40:304–10. 10.1016/S0735-1097(02)01965-4
    1. Shafiq A, Brawner CA, Aldred HA et al. . Prognostic value of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. The Henry Ford HospITal CardioPulmonary EXercise Testing (FIT-CPX) project. Am Heart J 2016;174:167–72. 10.1016/j.ahj.2015.12.020
    1. Edelmann F, Gelbrich G, Düngen HD et al. . Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011;58:1780–91. 10.1016/j.jacc.2011.06.054
    1. McManus DD, Hsu G, Sung SH et al. . Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc 2013;2:e005694 10.1161/JAHA.112.005694
    1. Schotten U, Verheule S, Kirchhof P et al. . Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011;91:265–325. 10.1152/physrev.00031.2009
    1. Daccarett M, Badger TJ, Akoum N et al. . Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol 2011;57:831–8. 10.1016/j.jacc.2010.09.049
    1. Shantsila E, Shantsila A, Blann AD et al. . Left ventricular fibrosis in atrial fibrillation. Am J Cardiol 2013;111:996–1001. 10.1016/j.amjcard.2012.12.005
    1. Weber KT. The proinflammatory heart failure phenotype: a case of integrative physiology. Am J Med Sci 2005;330:219–26. 10.1097/00000441-200511000-00004
    1. Endemann DH, Touyz RM, Iglarz M et al. . Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004;43:1252–7. 10.1161/01.HYP.0000128031.31572.a3
    1. Deswal A, Richardson P, Bozkurt B et al. . Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF). J Card Fail 2011;17:634–42. 10.1016/j.cardfail.2011.04.007
    1. Izawa H, Murohara T, Nagata K et al. . Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005;112:2940–5. 10.1161/CIRCULATIONAHA.105.571653

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir